The generic version of Trajenta (linagliptin), a DPP-4 inhibitor class, has applied for reimbursement pricing ahead of its launch in June.

This year, generic market is drawing attention to Trajenta. With the exclusive rights for Trajenta is set to expire, after Forxiga and Januvia last year, the diabetes market is expected to see new competition this year.

According to industry reports on the 4th, Trajenta generics applied for reimbursement pricing. Subsequently, the Health Insurance Review and Assessment Service (HIRA) started the pricing process.

It is expected that Trajenta generics would be listed on June 9 when the substance patent of the original drug expire